Figure 2.

Response of high-grade glioma to local therapy with a cumulated 2.2-GBq dose of [⁹⁰Y]Y-DOTA-TOC given in three cycles (from left to right: study before therapy, control study 3 months after second dose, control study 3 months after third dose, and control study 23 months after third dose). (A–F) T1-weighted enhanced MR images show diminishing contrast agent in tissue surrounding resection cavity throughout therapy. (A–J) [⁶⁸Ga]Ga-DOTA-TOC PET images representing somatostatin receptor status show increased tracer uptake around resection cavity before therapy (G) and normalization in control studies (A–J). Adapted from [103]. This research was originally published in JNM. Heute D, Kostron H, von Guggenberg E, Ingorokva S, Gabriel M, Dobrozemsky G, et al. Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC. J Nucl Med. 2010;51(3):397-400. © SNMMI.